Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia

SWOG S9917

James R. Marshall, Catherine M. Tangen, Wael A. Sakr, David P. Wood, Donna L. Berry, Eric A. Klein, Scott M. Lippman, Howard L. Parnes, David S. Alberts, David F. Jarrard, W. Robert Lee, J. Michael Gaziano, E. David Crawford, Benjamin Ely, Michael Ray, Warren Davis, Lori M. Minasian, Ian M. Thompson

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a potential premalignant lesion marking an increased risk of prostate cancer and substantial evidence suggests that men with HGPIN are in need of prostate cancer prevention. In vitro, in vivo, epidemiologic, and clinical trial evidence that selenium supplementation protects against prostate cancer motivated the study we report here: a double-blind, randomized, placebo-controlled trial of selenium 200 (μg/d) as selenomethionine in men with HGPIN. The primary endpoint was progression of HGPIN to prostate cancer over a 3-year period. This National Cancer Institute Intergroup trial was coordinated by the Southwest Oncology Group (SWOG). Of 619 enrolled patients, 423 randomized men with HGPIN (212 selenium and 211 placebo) were eligible (by central pathology review) and included in the primary analysis. Three-year cancer rates were 36.6% (placebo) versus 35.6% (selenium; P = 0.73, adjusted). The majority of patients who developed cancer on trial (70.8%, selenium and 75.5%, placebo) had a Gleason score of 6 or less than 6; there were no differences in Gleason scores between the two arms. Subset analyses included the finding of a nonsignificantly reduced prostate cancer risk (relative risk = 0.82; 95% CI: 0.40-1.69) in selenium versus placebo patients in the lowest quartile of baseline plasma selenium level (<106 ng/mL). Overall, and in all other subsets defined by baseline blood selenium levels, selenium supplementation had no effect on prostate cancer risk. The 36% prostate cancer rate in men with HGPIN indicates the association of this lesion with an elevated prostate cancer risk. Future study in this setting should focus on selenium-deficient populations and selenium pharmacogenetics.

Original languageEnglish (US)
Pages (from-to)1761-1769
Number of pages9
JournalCancer Prevention Research
Volume4
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Prostatic Intraepithelial Neoplasia
Selenium
Prostatic Neoplasms
Placebos
Neoplasm Grading
Selenomethionine
National Cancer Institute (U.S.)
Pharmacogenetics
Neoplasms
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marshall, J. R., Tangen, C. M., Sakr, W. A., Wood, D. P., Berry, D. L., Klein, E. A., ... Thompson, I. M. (2011). Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prevention Research, 4(11), 1761-1769. https://doi.org/10.1158/1940-6207.CAPR-10-0343

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia : SWOG S9917. / Marshall, James R.; Tangen, Catherine M.; Sakr, Wael A.; Wood, David P.; Berry, Donna L.; Klein, Eric A.; Lippman, Scott M.; Parnes, Howard L.; Alberts, David S.; Jarrard, David F.; Lee, W. Robert; Gaziano, J. Michael; Crawford, E. David; Ely, Benjamin; Ray, Michael; Davis, Warren; Minasian, Lori M.; Thompson, Ian M.

In: Cancer Prevention Research, Vol. 4, No. 11, 11.2011, p. 1761-1769.

Research output: Contribution to journalArticle

Marshall, JR, Tangen, CM, Sakr, WA, Wood, DP, Berry, DL, Klein, EA, Lippman, SM, Parnes, HL, Alberts, DS, Jarrard, DF, Lee, WR, Gaziano, JM, Crawford, ED, Ely, B, Ray, M, Davis, W, Minasian, LM & Thompson, IM 2011, 'Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917', Cancer Prevention Research, vol. 4, no. 11, pp. 1761-1769. https://doi.org/10.1158/1940-6207.CAPR-10-0343
Marshall, James R. ; Tangen, Catherine M. ; Sakr, Wael A. ; Wood, David P. ; Berry, Donna L. ; Klein, Eric A. ; Lippman, Scott M. ; Parnes, Howard L. ; Alberts, David S. ; Jarrard, David F. ; Lee, W. Robert ; Gaziano, J. Michael ; Crawford, E. David ; Ely, Benjamin ; Ray, Michael ; Davis, Warren ; Minasian, Lori M. ; Thompson, Ian M. / Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia : SWOG S9917. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 11. pp. 1761-1769.
@article{18b42289d125421bb5c8ac0b4b614e73,
title = "Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917",
abstract = "The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a potential premalignant lesion marking an increased risk of prostate cancer and substantial evidence suggests that men with HGPIN are in need of prostate cancer prevention. In vitro, in vivo, epidemiologic, and clinical trial evidence that selenium supplementation protects against prostate cancer motivated the study we report here: a double-blind, randomized, placebo-controlled trial of selenium 200 (μg/d) as selenomethionine in men with HGPIN. The primary endpoint was progression of HGPIN to prostate cancer over a 3-year period. This National Cancer Institute Intergroup trial was coordinated by the Southwest Oncology Group (SWOG). Of 619 enrolled patients, 423 randomized men with HGPIN (212 selenium and 211 placebo) were eligible (by central pathology review) and included in the primary analysis. Three-year cancer rates were 36.6{\%} (placebo) versus 35.6{\%} (selenium; P = 0.73, adjusted). The majority of patients who developed cancer on trial (70.8{\%}, selenium and 75.5{\%}, placebo) had a Gleason score of 6 or less than 6; there were no differences in Gleason scores between the two arms. Subset analyses included the finding of a nonsignificantly reduced prostate cancer risk (relative risk = 0.82; 95{\%} CI: 0.40-1.69) in selenium versus placebo patients in the lowest quartile of baseline plasma selenium level (<106 ng/mL). Overall, and in all other subsets defined by baseline blood selenium levels, selenium supplementation had no effect on prostate cancer risk. The 36{\%} prostate cancer rate in men with HGPIN indicates the association of this lesion with an elevated prostate cancer risk. Future study in this setting should focus on selenium-deficient populations and selenium pharmacogenetics.",
author = "Marshall, {James R.} and Tangen, {Catherine M.} and Sakr, {Wael A.} and Wood, {David P.} and Berry, {Donna L.} and Klein, {Eric A.} and Lippman, {Scott M.} and Parnes, {Howard L.} and Alberts, {David S.} and Jarrard, {David F.} and Lee, {W. Robert} and Gaziano, {J. Michael} and Crawford, {E. David} and Benjamin Ely and Michael Ray and Warren Davis and Minasian, {Lori M.} and Thompson, {Ian M.}",
year = "2011",
month = "11",
doi = "10.1158/1940-6207.CAPR-10-0343",
language = "English (US)",
volume = "4",
pages = "1761--1769",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia

T2 - SWOG S9917

AU - Marshall, James R.

AU - Tangen, Catherine M.

AU - Sakr, Wael A.

AU - Wood, David P.

AU - Berry, Donna L.

AU - Klein, Eric A.

AU - Lippman, Scott M.

AU - Parnes, Howard L.

AU - Alberts, David S.

AU - Jarrard, David F.

AU - Lee, W. Robert

AU - Gaziano, J. Michael

AU - Crawford, E. David

AU - Ely, Benjamin

AU - Ray, Michael

AU - Davis, Warren

AU - Minasian, Lori M.

AU - Thompson, Ian M.

PY - 2011/11

Y1 - 2011/11

N2 - The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a potential premalignant lesion marking an increased risk of prostate cancer and substantial evidence suggests that men with HGPIN are in need of prostate cancer prevention. In vitro, in vivo, epidemiologic, and clinical trial evidence that selenium supplementation protects against prostate cancer motivated the study we report here: a double-blind, randomized, placebo-controlled trial of selenium 200 (μg/d) as selenomethionine in men with HGPIN. The primary endpoint was progression of HGPIN to prostate cancer over a 3-year period. This National Cancer Institute Intergroup trial was coordinated by the Southwest Oncology Group (SWOG). Of 619 enrolled patients, 423 randomized men with HGPIN (212 selenium and 211 placebo) were eligible (by central pathology review) and included in the primary analysis. Three-year cancer rates were 36.6% (placebo) versus 35.6% (selenium; P = 0.73, adjusted). The majority of patients who developed cancer on trial (70.8%, selenium and 75.5%, placebo) had a Gleason score of 6 or less than 6; there were no differences in Gleason scores between the two arms. Subset analyses included the finding of a nonsignificantly reduced prostate cancer risk (relative risk = 0.82; 95% CI: 0.40-1.69) in selenium versus placebo patients in the lowest quartile of baseline plasma selenium level (<106 ng/mL). Overall, and in all other subsets defined by baseline blood selenium levels, selenium supplementation had no effect on prostate cancer risk. The 36% prostate cancer rate in men with HGPIN indicates the association of this lesion with an elevated prostate cancer risk. Future study in this setting should focus on selenium-deficient populations and selenium pharmacogenetics.

AB - The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic intraepithelial neoplasia (HGPIN) has been identified as a potential premalignant lesion marking an increased risk of prostate cancer and substantial evidence suggests that men with HGPIN are in need of prostate cancer prevention. In vitro, in vivo, epidemiologic, and clinical trial evidence that selenium supplementation protects against prostate cancer motivated the study we report here: a double-blind, randomized, placebo-controlled trial of selenium 200 (μg/d) as selenomethionine in men with HGPIN. The primary endpoint was progression of HGPIN to prostate cancer over a 3-year period. This National Cancer Institute Intergroup trial was coordinated by the Southwest Oncology Group (SWOG). Of 619 enrolled patients, 423 randomized men with HGPIN (212 selenium and 211 placebo) were eligible (by central pathology review) and included in the primary analysis. Three-year cancer rates were 36.6% (placebo) versus 35.6% (selenium; P = 0.73, adjusted). The majority of patients who developed cancer on trial (70.8%, selenium and 75.5%, placebo) had a Gleason score of 6 or less than 6; there were no differences in Gleason scores between the two arms. Subset analyses included the finding of a nonsignificantly reduced prostate cancer risk (relative risk = 0.82; 95% CI: 0.40-1.69) in selenium versus placebo patients in the lowest quartile of baseline plasma selenium level (<106 ng/mL). Overall, and in all other subsets defined by baseline blood selenium levels, selenium supplementation had no effect on prostate cancer risk. The 36% prostate cancer rate in men with HGPIN indicates the association of this lesion with an elevated prostate cancer risk. Future study in this setting should focus on selenium-deficient populations and selenium pharmacogenetics.

UR - http://www.scopus.com/inward/record.url?scp=81555202982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81555202982&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-10-0343

DO - 10.1158/1940-6207.CAPR-10-0343

M3 - Article

VL - 4

SP - 1761

EP - 1769

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 11

ER -